← Cancer trial database
Trial
Non-small cell lung cancer

Phase 2 sacituzumab govitecan (TROP2 ADC) ± ivonescimab (PD-1×VEGF bispecific) in AGA+ NSCLC

Trial status

Currently Recruiting

Status as of

Got an update?
Trial ID
NCT07393555 on ClinicalTrials.gov
Cancer type
Non-Small Cell Lung Cancer (NSCLC)
Stage of research
Exploratory
Location
CA, GA, ID, IL, MI, MO, MT, NH, OH, VT, WI (US, multi-center)
Published in
New in Oncology - Nov 19, 2026

This randomized Phase 2 Lung-MAP sub-study (SWOG Cancer Research Network) tests whether adding ivonescimab to sacituzumab govitecan improves outcomes versus either agent alone in previously treated, stage IV or recurrent NSCLC with an actionable genomic alteration (ALK, EGFR, HER2/ERBB2, MET, NTRK, RET, or ROS1), after appropriate targeted therapy and platinum-based chemotherapy and without prior PD-1/PD-L1 therapy. Sacituzumab govitecan (Gilead Sciences) is a TROP2-targeted antibody–drug conjugate that delivers SN-38 (a topoisomerase I inhibitor payload) into tumor cells, aiming to extend activity beyond driver-targeted TKIs. Ivonescimab (Akeso) is a PD-1×VEGF bispecific antibody intended to both release immune inhibition and suppress tumor angiogenesis, a dual mechanism designed to deepen and prolong responses compared with PD-1 blockade alone. The key commercial/scientific angle is a “post-targeted-therapy” strategy for AGA+ disease, where many patients have already exhausted genotype-matched TKIs and then move to platinum-based chemotherapy ± immunotherapy, followed by single-agent chemo and/or docetaxel-based combinations; this trial asks whether an ADC and an IO/anti-VEGF bispecific can reset disease control after prior targeted therapy and platinum-based chemotherapy.

More in non-small cell lung cancer

See all entries in non-small cell lung cancer →